Patrick Andrew Brown MD

Pediatric Hematology & Oncology•Baltimore, MD

Pediatric Hematologic Oncology

Associate Professor of Oncology, Assistant Professor of Pediatrics, Johns Hopkins University School of Medicine; Director, Pediatric Leukemia and Lymphoma Program

Join to View Full Profile

600 N Wolfe StBaltimore, MD 21287
Phone+1 410-955-6132
Fax+1 410-955-8897

Education & Training

Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 2001 - 2004
Johns Hopkins UniversityResidency, Pediatrics, 1998 - 2001
Medical University of South CarolinaClass of 1998

Certifications & Licensure

MD State Medical License 2001 - 2022

Clinical Trials

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
ACTIVE_NOT_RECRUITING
PHASE3
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Start of enrollment: 2011 Feb 09
Completed
Phase 1, Phase 2
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
ACTIVE_NOT_RECRUITING
PHASE3
Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Start of enrollment: 2010 Oct 01
Terminated
Phase 1, Phase 2
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. Start of enrollment: 2013 Aug 20
Completed
Phase 2
A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL Start of enrollment: 2014 Jan 06
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

9 citations
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
Kevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, Alexandra Dreyzin, Anant Vatsayan
Blood Advances. 2023-06-27
7 citations
NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization.
Sonali Narang, Nikki A Evensen, Jason Saliba, Joanna Pierro, Mignon L Loh
Genome Biology. 2023-04-04
20 citations
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
Alan S Wayne, Van Huynh, Nobuko Hijiya, Rayne H Rouce, Patrick A Brown
Haematologica. 2023-03-01

Abstracts/Posters

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
Patrick A. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report ...
Patrick A. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Single Cell Sequencing Reveals Heterogeneity of Gene Expression in KMT2A Rearranged Infant ALL at Relapse Compared to Diagnosis
Patrick A. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures